Navigation Links
Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights
Date:7/30/2008

decrease was partially offset by an increase in development costs for ANA773 in the second quarter of 2008.

General and administrative expenses were $2.0 million for the second quarter of 2008, compared to $2.3 million for the second quarter of 2007. The $0.3 million decrease primarily resulted from cost savings derived from Anadys' completed strategic restructuring.

Operating expenses were $7.5 million for the second quarter of 2008, compared to $9.3 million for the second quarter of 2007. Included as a component of Anadys' operating expenses were non-cash, share-based expenses of $0.7 million and $1.0 million for the second quarter of 2008 and 2007, respectively.

The net loss was $7.1 million for the second quarter of 2008, compared to a net loss of $7.0 million for the second quarter of 2007. Basic and diluted net loss per common share was $0.25 in the second quarter of 2008, compared to $0.24 in the second quarter of 2007. Non-cash share-based expense resulted in a $0.02 and $0.04 increase in basic and diluted net loss per share for the three months ended June 30, 2008 and 2007, respectively.

During the six months ended June 30, 2008 the Company had no revenue, compared to $2.4 million for the same period in 2007. The revenue recognized in the first six months of 2007 was primarily derived from the amortization of an upfront payment and a milestone payment under a prior collaboration. For the six months ended June 30, 2008, Anadys reported a net loss of $14.5 million, compared to $13.7 million for the same period last year. Basic and diluted net loss per common share was $0.51 for the six months ended June 30, 2008, compared to $0.48 for the same period in 2007.

Recent Development Program Highlights

-- Initiation of Phase I Clinical Trial of ANA598. In June, Anadys announced that dosing in healthy volunteers had commenced in a Phase I study of ANA598, the Company's non-nucleoside HCV polymerase inhibitor. Following compl
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Anadys Pharmaceuticals to Report Second Quarter 2008 Financial Results
2. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
3. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
6. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
7. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
8. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
9. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
10. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Tooth decay is an epidemic in American children with ... The World Health Organization says that worldwide, 60–90% ... What are the long-term effects of this transmissible infection? ... the oral bacterial imbalance and serious systemic issues like heart ... is also 100% preventable? Answer: there has been no way ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 A ... portable models, from Cole-Parmer is designed to meet ... line includes: , The new Cole-Parmer® MS-3400 ... workhorses in the lab. They ensure a powerful ... plasma specimen separation. Their standard four-place swinging buckets ...
(Date:5/16/2013)... , May 16, 2013 Scientists at the ... Beijing , and the California ... demonstrated a novel therapy for reversing memory decline in ... they find significant cognitive improvement in advanced stage AD ... mechanism for reversing cognitive decline for advanced stage AD ...
(Date:5/16/2013)... VA (PRWEB) May 16, 2013 BioInformatics ... Primary Cells & Stem Cell-Derived Cells: Current and Future ... the number of suppliers in the primary cells market ... what cell types are used most often, how satisfied ... the market size and anticipated growth rate. , ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3Cole-Parmer Offers Enhanced Selection of Centrifuges 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... for the faint of heart. Global competition and offshore manufacturing ... with rising unemployment, the need to retrain workers, and a ... for new ways to survive and grow. , ,If ... Dr. Raj Veeramani, UW Professor of Engineering and Business and ...
... O'Malley, D.O. established his practice, O'Malley Family Medicine, ... that practicing ndependently would enable him to provide ... a solo practitioner build a thriving practice in ... essential," says O'Malley. "That's why I sought to ...
... of Wisconsin and Delta Dental Plan of New Jersey ... made by Aetna, Ameritas Life Insurance Corp., Delta Dental ... America, MetLife and Dental Benefit Providers (the dental subsidiary ... in a cooperative technology venture to enhance a platform ...
Cached Biology Technology:University Consortium Enables Transformation and Survival for Wisconsin Businesses 2University Consortium Enables Transformation and Survival for Wisconsin Businesses 3Computer Card Supports Solo Doctor 2
(Date:5/17/2013)... Researchers at Rutgers, The State University of New Jersey, ... proprietary new formulation called Visikol TM that effectively ... be used in place of chloral hydrate, which is ... but which is tightly regulated by the Drug Enforcement ... , Clearing solutions, or clearing agents, are vital for ...
(Date:5/17/2013)... 17, 2013, Shenzhen, China---- Why Tibetan antelope can ... Plateau? In a collaborative research published in ... and other institutes provide evidence that some genetic ... to harsh highland environments. The data in this ... genetic mechanisms and the biology of other ruminant ...
(Date:5/17/2013)... Societies for Experimental Biology (FASEB) released a new ... trends highlighting the devastating impact of sequestration on the ... follows a May 15th Senate Appropriations Committee hearing featuring ... the $1.6 billion cut the agency sustained in FY ... on the scientific community." , According to data ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... Berkeley -- Biologists have tracked down genes that control the ... similar to the genes used by humans to set up ... finding, reported online in advance of publication in Nature ... same genes have been responsible for establishing the left-right asymmetry ...
... Station (SRS) Fisheries Research Biologist Wendell Haag, Ph.D., received ... during a ceremony today at the White House. Haag ... the award, which is the highest honor that a ... States. The Presidential Early Career Award for ...
... 19, 2008 Researchers at UT Southwestern Medical Center have ... role in defending the lungs against invading pathogens is responsible ... older adults. The same mutation may also be associated with ... gene that UT Southwestern scientists have linked with idiopathic pulmonary ...
Cached Biology News:Snails and humans use same genes to tell right from left 2Snails and humans use same genes to tell right from left 3Snails and humans use same genes to tell right from left 4Haag honored with Presidential Early Career Scientists Award 2UT Southwestern researchers identify gene linked to inherited form of fatal lung disease 2UT Southwestern researchers identify gene linked to inherited form of fatal lung disease 3
... is a fully automated microplate luminescence ... widest possible range of applications based ... assays luciferase, -galactosidase, gene activities with ... Luminescent Immunoassays Cell-based assays ...
... dispensers save space and organize gloves, ... garb. They are the perfect benchtop ... in labs, processing and manufacturing. Clear ... the particles they attract. Open-slot design ...
... handy dispensers save space and organize ... other garb. They are the perfect ... used in labs, processing and manufacturing. ... and the particles they attract. Many ...
... to the D-2000, except that it uses a ... wavelength range and comes with a shutter (controlled ... D-2000 Deuterium Light Source produces a powerful, ... versions of the light source are available, providing ...
Biology Products: